First Choice Neurology

Alzheimer’s

Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients

By Jeffrey Gelblum, MD As a practicing neurologist with over 25 years of experience treating Alzheimer’s disease, I strongly oppose the proposed intention of Centers for Medicare & Medicaid Services (CMS) to restrict coverage of anti-amyloid antibody therapy to only those patients who must participate in an approved hospital-based clinical trial (Coverage with Evidence Development, …

Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients Read More »

World Alzheimer’s Day: Alzheimer’s, Dementia, and the Brain

Today is World Alzheimer’s Day. It’s a day to celebrate to create awareness about the disease and to reduce the stigmatization and lack of information surrounding dementia. While World Alzheimer’s Month offers a longer period of time for Alzheimer’s or dementia associations worldwide to raise awareness, World Alzheimer’s Day marks the focal point of the …

World Alzheimer’s Day: Alzheimer’s, Dementia, and the Brain Read More »

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients

Biogen is providing its new Alzheimer’s drug Aduhelm free to some patients because of slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as aducanumab, the $56,000-a-year drug helps patients. There is also uncertainty about reimbursement from Medicare. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) …

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »

First Florida Patient to Receive Biogen Aducanumab Infusion

Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly infusion treatment for early-stage Alzheimer’s patients. The drug works to decrease amyloid plaque in the brain, which is a marker for Alzheimer’s disease. According to Dr. …

First Florida Patient to Receive Biogen Aducanumab Infusion Read More »

Lumbar Puncture for Cerebrospinal Fluid is a Vital Tool to Assess Amyloid Build Up in Alzheimer’s

In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause dementia. For example, amyloid and tau proteins build up in Alzheimer’s disease, and their levels can be measured in CSF. These abnormalities contribute to the …

Lumbar Puncture for Cerebrospinal Fluid is a Vital Tool to Assess Amyloid Build Up in Alzheimer’s Read More »

Medicare Sees a Growing Demand for Cognitive Assessment with Patients Suffering from Memory Disorders

Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the specific daily impact of dementia on my patients and allows me to implement a meaningful treatment plan. This plan can include medication as well as …

Medicare Sees a Growing Demand for Cognitive Assessment with Patients Suffering from Memory Disorders Read More »

FDA Approves Promising Alzheimer’s Treatment

Leading Florida Neurologists Available to Speak about Biogen Aducanumab Treatment Alzheimer’s patients and their families, as well as the medical community, are celebrating today’s decision by the FDA to approve Biogen’s Aducanumab, a promising infusion treatment for Alzheimer’s patients. Dr. Jeffrey Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, …

FDA Approves Promising Alzheimer’s Treatment Read More »

Larger Clinical Trial for Alzheimer’s Drug Donanemab Starting Soon

Eli Lilly’s clinical trial of the experimental drug donanemab appears to have successfully slowed cognitive decline in patients with the early symptoms of Alzheimer’s. The TRAILBLAZER-ALZ clinical trial was a relatively small, placebo-controlled, double-blind, multi-center Phase 2 study measuring the safety, tolerability, and efficacy of donanemab in patients with early symptomatic Alzheimer’s. Clinical Trial Results …

Larger Clinical Trial for Alzheimer’s Drug Donanemab Starting Soon Read More »

Alzheimer’s Patients and Holiday Gatherings

The holidays can be a stressful time, especially for families of a loved one diagnosed with Alzheimer’s disease. When a family member has dementia or Alzheimer’s disease, the family dynamic changes dramatically. Nowhere is this more evident than at holiday gatherings. Here are a few tips for families and caregivers: Prepare your family and friends. …

Alzheimer’s Patients and Holiday Gatherings Read More »

Translate »